Crisaborole

Brand names: Eucrisa ยท Active ingredient: Crisaborole

In short: EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Forms & strengthsOintment: 20 mg of crisaborole per gram (2%) of white to off-white ointment.
LabelPfizer Laboratories Div Pfizer Inc
Label updatedSep 25, 2025

What is Crisaborole used for?

EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Crisaborole dosage

Apply a thin layer of EUCRISA twice daily to affected areas. Once clinical effect is achieved, consider reducing application to once daily .

EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use.

How to take Crisaborole โ€” instructions & advice from the label

Advise the patient or caregivers to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Advise patients to discontinue EUCRISA and seek medical attention immediately if signs or symptoms of hypersensitivity occur .

Administration Instructions

Advise patients or caregivers that EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use.

Warnings & precautions

Do not take this medicine if: EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA. Hypersensitivity should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy.

Crisaborole side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle-controlled clinical trials (Trial 1 and Trial 2), 1012 subjects 2 to 79 years of age with mild to moderate atopic dermatitis were treated with EUCRISA twice daily for 4 weeks. The adverse reaction reported by โ‰ฅ1% of EUCRISA-treated subjects is listed in Table 1.

Adverse Reaction | EUCRISA

Twice DailyN=1012

n (%) | VehicleTwice Daily

N=499

n (%)

Application site painRefers to skin sensations such as burning or stinging. | 45 (4) | 6 (1)

Less common (<1%) adverse reactions in subjects treated with EUCRISA included contact urticaria .

In one double-blind, vehicle-controlled trial including an initial open-label period (Trial 3), 497 subjects 3 months of age and older with mild to moderate atopic dermatitis received EUCRISA twice daily for up to 8 weeks. This was followed by a double-blind period, during which 135 subjects out of 270 randomized subjects received EUCRISA and 135 subjects received vehicle once daily for 52 weeks or until they developed a flare. The adverse reactions observed in the open-label period were similar to the known safety profile of twice daily treatment with EUCRISA. The adverse reactions observed with once daily treatment were similar to vehicle . โ€ฆ

About this medicine

EUCRISA contains 2% crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use. The active ingredient, crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor.

Crisaborole is described chemically as 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole. The empirical formula is C14H10BNO3 and the molecular weight is 251.1 g/mol.

The structural formula is represented below:

Crisaborole drug substance is freely soluble in common organic solvents such as isopropyl alcohol and propylene glycol, and insoluble in water.

Each gram of EUCRISA contains 20 mg of crisaborole in an ointment containing white petrolatum, propylene glycol, mono- and di-glycerides, paraffin, butylated hydroxytoluene, and edetate calcium disodium.

How it works: Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 609b77de-1ca3-4783-b8f5-01a9c0f1d77d. Read the full official label on DailyMed.

Related medicines

Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab